Media headlines about CareDx (NASDAQ:CDNA) have been trending somewhat negative recently, Accern reports. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. CareDx earned a media sentiment score of 0.00 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 0 out of 100, meaning that recent media coverage is extremely unlikely to have an effect on the company’s share price in the next several days.
A number of equities research analysts have commented on the company. Zacks Investment Research downgraded CareDx from a “buy” rating to a “hold” rating in a research report on Monday, July 24th. ValuEngine downgraded CareDx from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd.
CareDx (NASDAQ:CDNA) traded down 0.77% during midday trading on Friday, reaching $1.29. The company’s stock had a trading volume of 184,570 shares. The firm’s market cap is $27.63 million. The company has a 50 day moving average price of $1.18 and a 200 day moving average price of $1.55. CareDx has a 1-year low of $0.76 and a 1-year high of $5.06.
In related news, major shareholder Neil Gagnon acquired 63,120 shares of the business’s stock in a transaction on Friday, June 23rd. The shares were bought at an average cost of $1.10 per share, with a total value of $69,432.00. Following the completion of the transaction, the insider now directly owns 886,216 shares of the company’s stock, valued at approximately $974,837.60. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders purchased a total of 80,689 shares of company stock worth $87,815 over the last ninety days. Corporate insiders own 5.40% of the company’s stock.
CareDx Company Profile
CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.
Receive News & Ratings for CareDx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.